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A Steroid Receptor Coactivator, SRA, Functions
as an RNA and Is Present in an SRC-1 Complex
(GR), mineralocorticoids (MR), and progestins (PR). This
modulatory domain contains a strong and autonomous
transactivation function (AF1) that has been shown to
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The role of activated nuclear receptors is to direct the*Department of Cell Biology
²Department of Biochemistry assembly and stabilization of a preinitiation complex in
a transcriptionally permissive environment at the pro-Baylor College of Medicine
Houston, Texas 77030 moter of a target gene. This involves the functional inter-
action of the receptor with factors contained in the tran-
scription preinitiation complex (Tsai et al., 1987; Beato
and Sanchez-Pacheco, 1996) and with other DNA-boundSummary
transcription activators (Jonat et al., 1990). Such inter-
actions are necessary but not sufficient for accurateNuclear receptors play critical roles in the regulation
regulation of transcription. Initial findings that distinctof eukaryotic gene expression. We report the isola-
receptors interfere with or ªsquelchº each other's trans-tion and functional characterization of a novel tran-
activation (Meyer et al., 1989) indicated that commonscriptional coactivator, termed steroid receptor RNA
limiting factors were involved. Several biochemical andactivator (SRA). SRA is selective for steroid hormone
genetic screens have since identified a number of pro-receptors and mediates transactivation via their amino-
teins that interact with activated receptors. By fulfillingterminal activation function. We provide functional and
a number of functional criteria, these coregulators havemechanistic evidence that SRA acts as an RNA tran-
been defined as coactivators for nuclear receptors (Hor-script; transfected SRA, unlike other steroid receptor
witz et al., 1996; McKenna et al., 1999): they significantlycoregulators, functions in the presence of cyclohexi-
enhance transactivation without altering basal tran-mide, and SRA mutants containing multiple transla-
scriptional activity; when overexpressed, they specifi-tional stop signals retain their ability to activate steroid
cally reverse squelching between different receptors;receptor±dependent gene expression. Biochemical
and they contain autonomous, transferable activationfractionation shows that SRA exists in distinct ribo-
domains.nucleoprotein complexes, one of which contains the
Coactivators that have recently received considerablenuclear receptor coactivator steroid receptor coacti-
attention are members of the SRC gene family and thevator 1. We suggest that SRA may act to confer func-
ªcointegratorsº p300 and CBP. Steroid receptor coacti-tional specificity upon multiprotein complexes re-
vator 1 (SRC-1) was cloned in our laboratory as a generalcruited by liganded receptors during transcriptional
coactivator for nuclear receptors (Onate et al., 1995) andactivation.
has been termed variously as p160/NCoA-1 (Kamei et
al., 1996) or ERAP-160 (Halachmi et al., 1994). High-
Introduction lighting the critical physiological role of coactivators,
the targeted deletion of SRC-1 causes partial hormone
Nuclear receptors are members of a structurally and insensitivity (Xu et al., 1998). Other nuclear receptor co-
functionally related family of ligand-activated and se- activators have been subsequently identified and char-
quence-specific eukaryotic transcription factors. By mod- acterized that are structurally and functionally related
ulating the transcription of target genes in response to to SRC-1 (McKenna et al., 1999 and references therein).
their own ligands and other afferent signals, they play The cointegrators CREB-binding protein (CBP; Chrivia
key physiological roles in the regulation of development, et al., 1993) and the closely related adenovirus E1A-
metabolism, and reproduction. Receptor activation is a associated p300 (Eckner et al., 1994) are well character-
multifaceted cascade of events that results in the bind- ized as general coactivators that interact not only with
ing of the receptor to specific regulatory DNA sequences multiple nuclear receptors but with a wide variety of
and culminates in the modulation of target gene expres- other transcriptional activators.
sion (Tsai and O'Malley, 1994; Mangelsdorf and Evans, To date, the majority of receptor-interacting factors
1995). Common to nearly all nuclear receptors is the have been identified by genetic screens, such as the
activation function AF2 in the distal carboxyl terminus yeast two-hybrid system, typically using the LBD of a
of the ligand-binding domain (LBD). A highly conserved given nuclear receptor as bait. This approach has led
amphipathic helix in AF2 has been shown to be impor- to the identification of multiple AF2 coactivators with
tant for ligand binding and hormone-dependent trans- common structural and functional features. The ªclassi-
activation (Danielian et al., 1992; Vegeto et al., 1992; calº type I steroid receptors, however, exert transactiva-
Lanz and Rusconi, 1994). The variable amino-terminal tion via their amino-terminal transcription activation
domain of nuclear receptors is extended in the type I function, AF1. For some steroid receptors, AF1 and AF2
or ªclassicalº receptor subclass comprising the recep- have a distinct pattern of cell and promoter specificity
tors for androgens (AR), estrogens (ER), glucocorticoids (Bocquel et al., 1989; Tasset et al., 1990). Reasoning that
specificity in steroid receptor±mediated transactivation
might be provided by factors that associate with the³ To whom correspondence should be addressed (e-mail: berto@
bcm.tmc.edu). poorly conserved AF1, we searched for coregulators
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that interact with the amino-terminal AF1 domain of hu-
man PR (hPR). We report here the cloning and character-
ization of a novel transcription coregulator termed ste-
roid receptor RNA activator (SRA). We provide functional
and mechanistic evidence that SRA acts as an RNA
transcript and exists in a ribonucleoprotein complex that
contains the AF2 coactivator SRC-1.
Results
Characterization of SRA
In an attempt to find cofactors that interact with steroid
hormone receptors, our laboratory used different func-
tional domains of the hPR as baits in a yeast two-hybrid
screening system. We previously reported the isolation
and characterization of a protein, SRC-1, that interacts
with the hPR-LBD (Onate et al., 1995). We performed a
similar screen of a human B-lymphocyte library with the
AF1-containing amino terminus of hPRA (corresponding
to amino acids 165±567 of hPRB). Primary sequence
analysis of two positive clones from this screen indi-
cated a short open reading frame (ORF). The 39 exten-
sion of reverse-transcribed skeletal muscle poly(A)1
Figure 1. Characterization of SRA GenesRNA identified an extended ORF with sequence identical
(A) Structure of three SRA isoforms (I±III) deduced from screeningto the 59 ORF from the lymphocyte library.
of different cDNA and genomic DNA libraries from human andIn order to retrieve cDNAs encoding full-length SRA,
mouse. The sequences are identical in a ªcoreº region of 687 bpwe used conventional screening of three different hu-
(no shadow) but are divergent in their 59 and 39 sequences (distinct
man cDNA libraries from skeletal muscle, heart, and the shadings). The vertical lines indicate the location of the proposed
HeLa S3 cell line. We obtained 13 positive clones with termination codon of the putative open reading frame ORF1.
DNA sequences that were identical in a central region. (B) Northern analysis of human SRA gene expression. (Left panel)
Multiple tissue Northern blot, containing 2 mg of human poly(A)1Three variants of SRA were predicted, all containing
RNA from each of the tissues indicated at the top, was hybridizedunique 59 and 39 extensions beyond an identical 687 bp
with a cDNA probe corresponding to the core sequence of humancore sequence (Figures 1A and 2). We also screened a
SRA (A). Predominant transcripts of about 0.7±0.85 kb (double
human genomic DNA library and found two clones with arrows) and less abundant transcripts of 1.3±1.5 kb are apparent.
partial sequence identity with the original SRA clones. The blot was stripped and reprobed with b-actin to correct for RNA
Additionally, screening of a mouse genomic DNA library loading (bottom). (Right panel) Northern analysis of human tissue
culture RNA probed with the longest cDNA sequence of SRA ([A],identified 5 positive clones, and screening of a mouse
isoform III) indicates a cell line±specific expression of SRA isoforms.cDNA library found 14 positive clones, of which 2 re-
MCF-7 and T-47D cells have significantly higher levels of the smallervealed 75% identity to the human SRA cDNA (Figure
SRA transcript (open arrow) compared to other tissues, but they
2). Primary sequence analysis of clones from different express similar levels of the larger transcript (filled arrowhead). Total
human and mouse cDNA and genomic DNA libraries RNA was isolated from human cell lines as indicated and 15 mg
suggested that SRA represented a family of clones analyzed. The membrane was subsequently hybridized with b-actin
probe as an internal control for loading (bottom). Size markers arehighly homologous in a core sequence but divergent in
indicated on the right (kb).their 59 and 39 regions. Sequence comparison using the
A549, lung carcinoma; HeLa, epitheloid cervix; HepG2, hepatoblas-BLAST algorithm indicated no homologs but identified
toma; LNCaP, metastatic prostate adenocarcinoma; MCF-7, breast
partial SRA sequences isolated as HepG2-39UTR (ac- adenocarcinoma; T-47D, breast ductal carcinoma; 293, transformed
cession number D16861), expressed sequence tag clones, primary embryonal kidney.
and chromosome 5 BAC clone 319C17 (AC005214), al-
though no functions for these sequences were described. Northern analysis of poly(A)1-selected mRNA from dif-
To determine the expression patterns of the corre- ferent human tissue culture cell lines. All of the cell
sponding RNA, we performed Northern analysis using lines tested expressed the z0.85 kb doublet species,
a cDNA probe corresponding to the core sequence of whereas the smaller z0.7 kb species was expressed at
human SRA. Major transcripts of 0.7±0.85 kilobases (kb) significantly higher levels in the breast cancer cell lines
in length and less abundant transcripts of 1.3±1.5 kb MCF7 and T-47D, compared to the other cell lines inves-
were detected in a human multiple tissue Northern blot tigated (Figure 1B). This isoform-specific expression
(Clontech) (Figure 1B), indicating that the isolated cDNAs was conserved in mouse tissue (not shown). We con-
were likely to be full length. In addition, SRA was ex- cluded that multiple SRA isoforms are expressed quanti-
pressed at different levels in the tissues examined; tran- tatively in a tissue- and cell type±specific manner.
scripts were enriched in liver and skeletal muscle but
expressed at a low level in brain. Interestingly, the ex- SRA Is a Steroid Receptor±Specific Coactivator
pression of the two messages in the 0.7±0.85 kb doublet To investigate the functional role of SRA, we subcloned
appeared to be tissue specific in the multiple tissue the cDNAs into mammalian expression vectors and as-
blot. A cell line±specific expression of these isoforms sayed the effect of SRA on PR-dependent transactiva-
tion. HeLa cells were cotransfected with the CMV-hPR(represented by the doublet) was also observed in a
Steroid Receptor RNA Coactivator
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Figure 2. Primary Nucleotide Sequence Alignment of SRA Isoform
I cDNA from Human and Mouse
The nucleotides of mouse cDNA are indicated where they differ
from the human cDNA sequence. Brackets represent the boundaries
of the SRA core sequence. Arrows illustrate the location and orienta-
tion of the primer set used for SRA-specific RT-PCR (shown in
Figure 3. SRA Is a Steroid Hormone Receptor±Specific CoactivatorFigures 6 and 7). The Kozak consensus sequence is marked in
bold; circles indicate the putative translation initiation codons (ATG) (A) SRA enhances transcription mediated by steroid receptors. Thin-
targeted for mutation analysis (Figure 4); a consensus polyadenyla- layer chromatographs showing the chloramphenicol-acetyltransfer-
tion signal (AATAAAA) is boxed. ase (CAT) reporter activity as a response to steroid receptor±
mediated transactivation in the presence of SRA (1) or empty vector
(2). HeLa cells were transiently transfected with plasmids encoding
the human receptors for glucocorticoid (GR), androgen (AR), estro-and CMV-SRA (CMV, cytomegalovirus) along with (PRE)2- gen (ER), thyroid hormone (TRb), all-trans retinoic acid (RARg), 9-cis
TATA-CAT reporter (CAT, chloramphenicol acetyltrans- retinoic acid (RXRg), or with peroxisome proliferator±activated re-
ferase) and induced with progestin (R5020). We ob- ceptor (PPARg) along with their cognate hormone response element
served that SRA enhanced PR transactivation (Figure coupled to a TATA-CAT reporter gene and induced with their appro-
priate ligands or the PR antagonist RU486.3A; compare lanes 2 and 3) and that SRA did not alter
(B) SRA enhances transcription via the N-terminal activation domainthe activity of PR in the presence of its antagonist RU486
AF1 of steroid receptors. (Left panel) PR deletion mutants lacking(lane 4). Furthermore, SRA did not significantly elevate
either the ligand-binding domain (PRDLBD: lanes 1±4) or the amino-
the basal activity of the minimal promoter (lane 5). Similar terminal activation function (PRDAF1: lanes 5±8) were assayed as
transfection experiments with the human receptors for in (A). Similar experiments with rat GR or domains thereof excluded
GR, AR, ER, thyroid hormone (TR), retinoic acid± (RAR the DNA-binding domain (DBD) as a possible target for SRA (right
panel). The GR truncations were fused to the activation domain ofand RXR) or peroxisome proliferator±activated receptor
GAL4 to monitor transactivation. SRC-1 was used as control. MMTV-(PPAR), and CAT reporters containing cognate hormone
driven luciferase gene expression is shown as relative light unitsresponse elements revealed that SRA selectively en-
(RLU).
hanced steroid receptor±mediated transactivation (Fig- (C) Overexpression of SRA reverses squelching of PR by ER in a
ure 3A). SRA did not enhance transactivation induced dose-dependent manner. HeLa cells were transfected with PR and
by other activators such as GAL4, Sp1, E2F, E47, and ER expression plasmids (50 ng), MMTV-luciferase reporter (2.5 mg),
and different amounts of SRA (0±4 mg) and supplemented with 50forskolin-stimulated CREB (data not shown).
nM receptor-specific ligands R5020 or E2, or both, as indicated.We next found that SRA enhanced transactivation
Luciferase activities are shown as RLU per microgram of proteinthrough the N-terminal AF1 portion of steroid receptors.
assayed as the mean (6SD) of triplicate values.
Truncation of the A/B domain of the PR (PRDAF1) signifi- (D) PR transactivation is inhibited by digestion of endogenous SRA in
cantly reduced coactivation by SRA (Figure 3B, lanes 7 an oligonucleotide-dependent manner. HeLa cells were transfected
and 8), whereas transcription activation by PR lacking with PR expression plasmid (20 ng) and MMTV-luciferase reporter
(2.5 mg) together with different concentrations (200, 100, and 50 nM)the LBD (PRDLBD) was fully responsive to SRA (lanes
of SRA-specific, 29methoxyethyl-modified antisense deoxyoligo-1±4). In order to exclude the DNA-binding domain as
nucleotide (as), or sense control (s). Luciferase activities are showna mediator for SRA coactivation, we tested different
as the mean (6SD) of triplicate values.
domains of rat GR as fusion proteins with the activation
domain of GAL4 (Figure 3B, right panel). As expected,
neither the amino-terminally truncated GRDAF1 nor the SRC-1. These results indicated that SRA mediates tran-
scriptional activation of steroid receptors by a mecha-DNA-binding domain of rat GR (GR-DBD) responded to
SRA to enhance luciferase reporter activity. As a control, nism involving the AF1 of the receptors. We next tested
the possibility that intramolecular ªcrosstalkº betweenGRDAF1 enhanced reporter activity in the presence of
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the AF1 and AF2 of the receptor is mediated by SRA and
SRC-1 but found that coexpression of both coactivators
had only an additive effect on the coactivation of PR-
mediated transactivation (not shown). To better deter-
mine the coactivation potential of SRA in vivo, we trans-
fected different SRA clones into T-47D cells and tested
the ability of SRA to enhance the activity of endogenous
PR. All three isoforms of SRA cDNA, in addition to a
portion of the human genomic SRA, enhanced transacti-
vation mediated by the endogenous PR by 8- to 12-fold,
and the core domain of SRA was found to be necessary
and sufficient for this coactivation (not shown).
Another criterion for classification as a coactivator is
the ability of a factor to reverse interference (squelching)
by transcriptional activators with common coregulators.
To ask if SRA is a limiting factor that can be sequestered
by an excess of another receptor, we used a PR-regu-
lated gene reporter assay in the presence of ER (Figure
3C): while ligand-activated ER reduced the transcription
activity of PR by 50%, full PR transactivation was rees-
tablished by addition of SRA, confirming that SRA regu-
lates the transactivation of both PR and ER in a dose-
dependent manner and indicating that SRA is a limiting
cellular factor for steroid receptors.
In order to assess the effect of abrogation of endoge-
nous SRA on PR-mediated transcription, we developed
an assay in which SRA transcripts were selectively de-
Figure 4. Mutated SRA Constructs Enhance PR Transactivationgraded. By administration of stabilized antisense deoxy-
(A) Schematic presentation of SRA mutants. Top: SRA core cDNAoligonucleotides, we attempted to digest SRA by endog-
and deduced ORF map; selected restriction sites and presumptiveenous RNase H, an endoribonuclease that specifically
termination codon for ORF1 (TAA) are indicated; ªY,º location ofhydrolyzes the phosphodiester bonds of RNA/DNA hy- peptide sequence used to generate SRA-mAb; vertical lines in ORF
brids. Figure 3D shows that PR±target gene expression map, stop codons; white, putative initiation codons. Bottom: SRA
was reduced by z70% by cotransfection of an SRA mutants used in the transactivation studies presented and de-
scribed in (B) and (C). Triple numbers indicate total of stop codons inantisense 29methoxyethyl oligonucleotide, whereas the
each ORF; asterisks, point mutation(s); arrows, translation initiationcorresponding sense construct had no effect on PR
region of the thymidine kinase promoter (tk); the shade of graytransactivation. Similar experiments were performed
indicates reading frames of presumptive translation products: white,with three other SRA-specific deoxyoligonucleotides, all unconstrained; black, ORF1 (recognized by mAb); gray, ORF2; light
of which significantly reduced PR target gene expres- gray, ORF3.
sion. In addition, the antisense oligonucleotides were (B) Immunodetection and coactivation of transfected SRA mutants
indicate that SRA coactivates PR transactivation in an ORF-inde-capable of reducing reporter gene expression mediated
pendent manner. SRA mutants along with MMTV-Luc reporter andby endogenous receptor (not shown). These results im-
PR expression plasmid were transfected into COS cells and ana-ply that endogenous SRA has a direct impact on steroid-
lyzed for immunoreactivity to SRA antibody raised against a peptidemediated transcription in vivo. Together with the ability sequence deduced from the C terminus of ORF1 (left panel) and for
of SRA to enhance transactivation on minimal and natu- coactivation (right panel). Mutants are as follows: (1) N-terminal
ral promoters without altering basal transcription, these truncation at the intrinsic Kozak sequence (DATG) and (2) fusion
with translation initiation region of the tk in two different open read-results clearly characterized SRA as a bona fide coacti-
ing frames (tk-ORF1 and tk-ORF2). The constructs are illustrated invator, specific for the AF1 domain of steroid receptors.
(A). Protein size markers are indicated on the left. Fold coactivation
in relation to PR transcription as the mean (6SD) of triplicate values
SRA Does Not Exhibit Characteristics of a Protein is indicated on the right.
Sequence analysis of the SRA clones indicated an ORF (C) Enhancement of PR-mediated transactivation of the MMTV-Luc
reporter by various mutated SRA constructs shown schematicallyterminated at the 39 end of the core sequence (see Figure
in (A). Fold coactivation is indicated relative to expression of empty1A; a detailed ORF map is shown in Figure 4A: this ORF
vector (v) and shown as the mean (6SD) of triplicate values.is denoted ORF1). A second ORF, ORF2, contains a
SRA, wild-type SRA; SRA inv, cDNA of SRA expressed in 39±59consensus Kozak sequence in the 59 portion of the SRA orientation; ORF1, ORF2, ORF3, nonsense mutations at the BamHI
cDNA. This ORF2 corresponds to the presumed recep- site obliterating the Kozak sequence of two reading frames and
tor-interacting reading frame of the yeast hybrid clones. permitting only one putative translation product; YIle, mutant ORF2
with an additional point mutation altering an ATG (Figure 2) andHowever, an in-frame stop codon terminated GAL/SRA
generating an MfeI site; B, frameshift mutation at the BbsI site offusion products prematurely at the 59 end of the core
SRA; S, frameshift mutation at the SgrAI site; MS, frameshift muta-sequence. We concluded that the interaction of the origi-
tions at the MfeI and SgrAI sites; YMS, mutant MS with additionalnal yeast two-hybrid SRA clones with the AF1 of PR frameshift mutation at the BamHI site; YMBS, mutant ORF2 with
was unlikely to have been mediated by a protein product additional frameshift mutations at MfeI, BbsI, and SgrAI; ORF1DB/
encoded by ORF2 of SRA. ORF2DB/ORF3DB, 39 deletion at BbsI of the mutants ORF1, ORF2,
and ORF3, respectively.We next attempted to characterize the presumptive
Steroid Receptor RNA Coactivator
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SRA protein product. Surprisingly, all our efforts to gen-
erate SRA-encoded protein were unsuccessful. In vitro
translation of different SRA cDNAs did not result in de-
tectable levels of protein, whereas carboxy-terminal fu-
sions of SRA with GAL4 or GST produced the expected
translation products (not shown). In addition, GAL/SRA
fusion constructs failed to activate the UAS heterolo-
gous promoter, indicating that SRA did not possess
an intrinsic activation function. We then generated a
monoclonal antibody (mAb) against the peptide se-
quence encoded by the 39 end of the SRA core (ORF1).
In Western analysis, only ORF1 fusion constructs of
GAL/SRA and GST/SRA were immunoreactive (not
shown), whereas no proteins generated by expressed
SRA cDNAs were detectable in cell extracts. We con-
cluded that the SRA cDNA sequence did not encode a
viable translation product.
We then correlated the coactivation function of SRA
Figure 5. SRA Is an RNA Coactivatorwith its expression. Mutated SRA constructs were trans-
SRA does not require protein synthesis to enhance endogenousfected into cultured cells and analyzed in a side-by-
GR-mediated transactivation. Two separate groups of HeLa cells
side comparison for SRA ªimmunoreactivityº and for were transiently transfected with reporter MMTV-Luc (2 mg) along
coactivation of PR-mediated transactivation. The con- with different amounts of CMV-driven expression plasmids for SRA
structs tested were (1) a 59 truncation at the BamHI site (3, 2, 1, 0.5 mg), SRC-1 and CBP (3, 2, 1 mg), or empty vector (v; 3
mg) and treated with EtOH control (2) or dexamethasone (1). One set(Figure 4A), eradicating the consensus Kozak sequence,
of transfected cells was assayed for luciferase protein expressionand (2) a fusion of this truncated cDNA to the HSV-
(upper panel), the other set of cells incubated in medium containingthymidine kinase initiation sequence (tk) in two distinct
50 mM cycloheximide and subjected to RNA isolation and DNaseI
reading frames, producing tk-ORF1 and tk-ORF2. All digestion, followed by Northern analysis for luciferase RNA expres-
three SRA mutants enhanced PR-mediated transactiva- sion (lower panel). The Northern blot was hybridized with probes
tion (Figure 4B, right panel), whereas only one con- specific for cyclophilin (F) and luciferase RNA (Luc). Lane numbers
(bottom) are common to both assays. Dilution (10,000-fold) of RNAstructÐthe reading frame of which corresponded to
from cotransfected CMV-luciferase plasmid expression is shown asORF1Ðwas recognized by the mAb (4B, left panel). No
control in the Northern analysis (lane 17). A longer exposure of theendogenous SRA protein was detected that corre-
blot revealed low levels of luciferase transcripts in all samples that
sponded to the constrained translation of tk-ORF1. Im- were treated with dexamethasone.
portantly, screening of a panel of tissue culture cell lines
by matrix-bound SRA-mAb confirmed the absence of SRA Is an RNA Coactivator
endogenous SRA protein in these lines (not shown). We next focused our attention on the transcription prod-
Taken together, these results suggested to us that co- ucts of the cDNA encoding SRA. We designed an assay
activation by SRA was unlikely to be mediated by its for RNA-mediated transactivation by targeting endoge-
presumptive protein product. nous GR in HeLa cells cultured in the presence of the
In order to substantiate these results, we generated de novo protein synthesis inhibitor cycloheximide and
various SRA mutants and tested them in cell culture for asked if SRA retained the ability to coactivate GR-medi-
their ability to coactivate PR-dependent transcription. ated transcription. As controls, we used the coregulators
Figure 4A shows the sequence of the SRA mutants rela- SRC-1 and CBP, both of which interact with nuclear
tive to the original SRA clone. Several of the mutants receptors as proteins. Two separate pools of HeLa cells
lacked the ATGs in ORF1 and ORF2; others contained were transiently transfected with an identical mixture
mutations within the Kozak sequence, allowing a pre- of MMTV-luciferase reporter (MMTV, mouse mammary
sumptive translation of only one given reading frame tumor virus LTR) along with CMV-driven expression
(see legend to Figure 4A for details). Other constructs plasmids for SRA, SRC-1, CBP, or empty vector and
contained single or multiple frameshift mutations along treated with carrier or dexamethasone. One set of trans-
the core sequence, resulting in a ªmosaicº organization fected cells was subjected to a conventional luciferase
of reading frames, each containing approximately six protein assay for GR-mediated transactivation. The sec-
translational stop codons on average. A representative ond set of cells was first incubated in medium containing
assay of in vivo±expressed SRA mutants (Figure 4C) cycloheximide from 3 hr prior to transfection until har-
clearly demonstrates that most of the SRA mutants re- vesting and then subjected to Northern analysis for lucif-
tained the ability to enhance PR transcription by 8- to erase RNA expression. Figure 5 shows a representative
12-fold. Only SRA expressed in 39±59 orientation (SRA side-by-side comparison of luciferase expression as
inv) or 39 half-truncated versions of the ORF exclusion protein (upper half) and RNA (lower half). As expected,
mutations were inactive. Similar results were obtained we observed a hormone- and dose-dependent enhance-
with mutants of other SRA isoforms (not shown). These ment of transactivation by all coregulators in the ab-
results further suggested to us that the coactivation sence of cycloheximide (upper panel). The relatively low
exerted by SRA on steroid receptor transcription was coactivity for all coactivators resulted from lower protein
unlikely to be mediated by a translation product of the expression levels due to the necessarily shorter incuba-
tion time for cycloheximide-treated cells. In contrast,SRA gene.
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the Northern analysis for luciferase expression of the
set of cycloheximide-treated cells (lower panel) revealed
that SRA (lanes 5±8), but not SRC-1 (10±12) or CBP
(14±16), was able to enhance transcription under these
conditions. As a control, we assayed 35S-methionine in-
corporation in the two groups of cells and found that
the amount of cycloheximide used in our assays (50 mM)
abolished .99% of the total cellular translation products
(not shown). Moreover, a third control set of transfected
cells treated with cycloheximide and analyzed for lucif-
erase reporter activity produced relative light units cor-
responding to basal activity. The fact that only SRA and
not SRC-1 and CBP was capable of potentiating GR-
mediated transcription in the absence of de novo protein
synthesis was clear evidence that the functionality of
SRA was not contingent upon translation of the primary
SRA transcript.
SRA Is Present in a Distinct Steroid Receptor
Coregulator Complex
Given that functional RNAs are known to associate with
proteins as ribonucleoprotein complexes, we next asked
if SRA might function as a component of similar com-
plexes. To investigate protein±SRA interaction in a
steady-state situation in vivo, we fractionated whole-
cell extract from human T-47D cells on a Superose 6
column as previously described (McKenna et al., 1998).
One-half of the collected fractions were processed for
Western analysis using specific antibodies against tran-
scriptional coregulators, and the remainder of each frac-
tion was subjected to RNA isolation followed by SRA
transcript±specific RT-PCR and Southern analysis. We
validated our RT-PCR method by incubation of cell ex-
tract with SRA-specific antisense deoxyoligonucleo-
tides and subsequent digestion with endoribonuclease
(4 MDa for globular proteins) was determined at fraction 20 by silver
staining (not shown). Lower panels: SRA-specific RT-PCR and paral-
lel immunoblots with SRC-1-specific antibody of fractionated T-47D
cells after preincubation of the lysate with either nonspecific anti-
body (WCE 1 n.s. Ab) or SRC-1 antibody (WCE 1 SRC-1 Ab). In
addition to SRA, fractions 34 and 35 contained the AF2 coactivators
TIF2 and SRC-3 (McKenna et al., 1998 and not shown). Since SRC-3
was reported to be an exclusively nuclear protein (Suen et al., 1998),
it indicates that our lysis conditions extract complexes both of nu-
clear and cytoplasmic origin.
(B) Coimmunoprecipitations of SRA in fractionated cells. T-47D ly-
sates were fractionated as in (A), subsequently immunoprecipitated
with antibodies against p300 (middle) and SRC-1 (bottom), and ana-
lyzed for SRA by RT-PCR (left panels) or by parallel Western analysis
for precipitation of p300 (right). Numbers indicate fractions. sup.,
combined supernatant of both precipitation reactions; neg., RT-
PCR omitting reverse transcriptase; WCE, input lysate (note that
the conditions for immunoprecipitation of fractionated extracts did
not coprecipitate SRA in WCE).
(C) Coimmunoprecipitation of SRA with AR or SRC-1 in Xenopus
oocyte extracts. Ethidium bromide±stained agarose gel of SRA-
Figure 6. SRA Is Present in an SRC-1 Complex specific RT-PCR products from immunoprecipitation reactions (RT-
(A) Copurification of SRA and SRC-1 complexes by gel filtration PCR) and parallel SDS-PAGE analysis of precipitated proteins
chromatography. Upper panels: T-47D lysates (z400 mg) were frac- (PAGE). In vitro±transcribed RNAs for SRA, SRC-1, p300, AR and
tionated on a Superose 6 column and analyzed for total protein the AR mutant ARDAF1, TR, RXR, and Sp1 were injected along with
elution (A280 nm, top), SRC-1-specific RT-PCR (control), and SRA- L-35S-methionine into Xenopus laevis oocytes (as indicated at the
specific RT-PCR (SRA). RT-PCR analysis of z20 mg input whole-cell top) and the translation products subsequently targeted for immuno-
extract in the presence (WCE) or absence of reverse transcriptase precipitation (antibodies indicated at the left). n.s. Ab, nonspecific
(RT neg.) are shown to the right. Numbers indicate fractions. Elution antibody; aAR-LBD, polyclonal antibody against the C terminus of
peaks of molecular size markers are given for mammalian SWI/SNF androgen receptor (AR); ARDAF1, AF1-depleted AR; sup., superna-
complex (z2 MDa) and thyroglobulin (670 kDa); the void volume tant of immunoprecipitation reaction.
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RNase H, which destroyed the SRA signal in an oligonu- SRA was undetectable after immunoprecipitation using
a nonspecific antibody from cell lysates programmedcleotide- and dose-dependent manner (not shown). We
found that endogenous SRA specifically eluted in com- with SRA (lane 1). Similarly, SRA was not detected after
immunoprecipitation with an AR antibody from cell ly-plexes of 600±700 kDa (Figure 6A, fractions 34 and 35).
We verified that these fractions do not reflect a nonspe- sates injected with RNA encoding AR, although AR was
specifically precipitated (lane 2). In contrast, the AR anti-cific peak of proteins and RNA (Figure 6A, upper panels).
Western analysis indicated that SRA copurified with body precipitated SRA in a hormone-independent man-
ner in extracts from oocytes injected with RNAs for SRAfractions containing SRC-1 (Figure 6A, SRC-1). Interest-
ingly, SRA was not detected in fractions containing and AR (lanes 3 and 4). We next investigated the speci-
ficity of the interaction of SRA with SRC-1 and AR. Anp300/CBP (fractions 28±31). The colocalization of SRC-1
and SRA led us to consider that they may be part of a AR mutant lacking the amino-terminal domain (ARDAF1)
did not retain coinjected SRA (lane 11), although thecommon complex in vivo. Based on this assumption,
we attempted to alter the elution pattern of this putative supernatant clearly contained SRA (lane 6). However,
in oocytes containing SRC-1 in addition to SRA andcomplex by incubating cell lysates with anti-SRC-1 anti-
body and rabbit anti-mouse IgG prior to fractionation. ARDAF1, the antibody against the LBD of AR coprecipi-
tated SRA and SRC-1 (lane 12). In addition, immunopre-As predicted, this resulted in a clear shift of both the
SRA signal and SRC-1 immunoreactivity from fractions cipitation using a monoclonal antibody against SRC-1
from oocytes programmed with RNAs for SRA and34±35 to fractions 29±30 (Figure 6A, lower panel). To
exclude the possibility that the shifted SRC-1 was due SRC-1 clearly coprecipitated SRA and SRC-1 (lane 5),
verifying that SRA is in a stable association with SRC-1.to nonspecific antibody binding, the Western blots were
stripped and reprobed with anti-CBP antibody. The elu- Similarly, analysis of oocytes programmed with SRA,
TR, RXR, and SRC-1 and precipitated with TR antibodytion profile of CBP was the same irrespective of preincu-
bation of cell lysate with SRC-1 antibody (not shown). indicated SRA only in SRC-1-containing extracts (lane
19), verifying again the selectivity of SRA for steroidTo verify our findings that SRA associatesÐdirectly
or indirectlyÐwith SRC-1, we attempted to coimmuno- receptors and SRC-1. Taken together, we conclude that
SRA exists in a ribonucleoprotein complex containingprecipitate SRA and SRC-1. To quantitatively enrich SRA
in the cells subjected to fractionation, we transfected SRC-1 and that this complex is recruited by a steroid
receptor.HeLa cells with a plasmid encoding SRA. We then frac-
tionated the lysates and subjected the fractions to im-
munoprecipitation with antibodies against SRC-1 and Discussion
p300 prior to RT-PCR analysis. SRA was detected in the
anticipated fractions in both the inputs and the SRC-1 In this work we describe the isolation and functional
precipitates (Figure 6B, upper and lower panels, frac- characterization of a novel transcriptional coactivator
tions 34±36), but SRA was not coimmunoprecipitated termed SRA. SRA is different from other known coregu-
with p300 (middle panel). Parallel Western analysis indi- lators in that it functions as an endogenous RNA tran-
cated that p300 was specifically precipitated by anti- script. We have defined several different features of this
RNA: SRA is (1) a bona fide transcriptional coactivator,p300 antibody in the anticipated fractions. These results
verified our finding that SRA resides in a complex con- (2) selective for the AF1 of steroid receptors, (3) ex-
pressed as multiple isoforms in a cell-specific manner,taining SRC-1 but not p300 or CBP. To test the possibil-
ity that SRA might have a structural role in the SRC-1 and (4) present in a steady-state coregulator complex
with the AF2 coactivator SRC-1.complex, we treated cell extracts with RNase prior to
fractionation. These extracts did not produce SRA sig- We have described the isolation of three SRA isoforms
deduced from sequencing of different cDNAs and geno-nals in the RT-PCR analysis, whereas SRC-1 was detect-
able in fractions 35±36 (not shown), suggesting that SRA mic clones from different species. When overexpressed
in mammalian cells, recombinant SRA, regardless ofdoes not have a vital structural role in SRC-1 complexes.
Taken together, biochemical fractionation experiments isoform or origin, enhanced steroid receptor±mediated
transactivation without significantly enhancing the levelindicated that SRA is a component of distinct ribo-
nucleoprotein complexes, one of which contains the of basal transcription of minimal or natural promoters.
In assays of endogenous PR±mediated transactivation,nuclear receptor coactivator SRC-1.
Having established that SRA was present in SRC-1- a typical enhancement of receptor gene activity of z10-
fold was achieved by coexpression of SRA. Antisensecontaining complexes, we wished to know whether SRA
interacted with steroid receptors as a component of a deoxyoligonucleotides added to cells reduced steroid
receptor±induced transcription by up to 70%. In addi-ribonucleoprotein complex. To address this possibility,
we performed coimmunoprecipitation experiments us- tion, we have shown that SRA reverses steroid receptor
squelching in a dose-dependent manner. Hence, SRAing a previously described expression system in Xeno-
pus oocytes (Wong et al., 1995). In vitro±generated RNAs exhibits many characteristics expected of a bona fide
coactivator.encoding SRA, SRC-1, p300, AR and the AR mutant
ARDAF1, TR, RXR, and the nonnuclear receptor tran- Despite certain functional similarities, SRA differs in
some important aspects from many other coactivatorsscription factor Sp1, along with L-35S-methionine, were
injected into oocytes and their cell extracts subjected in that its coactivation is selective and that it is an RNA.
We have presented several independent lines of evi-to coimmunoprecipitation with antibodies against the
expected protein products. Figure 6C shows the cDNA dence that indicate that SRA selectively enhances ste-
roid receptor±mediated transactivation but does not in-products generated by SRA-specific RT-PCR of the vari-
ous immunoprecipitates along with SDS-PAGE analysis. fluence transactivation by type II nuclear receptors or
Cell
24
by other transcription factors. In addition, using in situ regulate the activity of a family of transcriptional acti-
hybridization analysis we have obtained evidence for vators.
both a selective expression pattern of SRA and a general Functional evidence indicates that coregulators asso-
colocalization in brain tissue with members of the ste- ciate with nuclear receptors as members of multiprotein
roid receptor family (data not shown). In our coimmuno- complexes (Rachez et al., 1998). It has been shown that
precipitation assays it appears that, unless SRC-1 is hormone-activated receptors can recruit the coactiva-
coexpressed, the N-terminal domain of steroid recep- tors of the SRC-1 family, the cointegrators p300 and
tors is required for binding of SRA. In our reporter gene CBP, histone acetyltransferase activity P/CAF, or chro-
assay, SRA per se fails to enhance transcriptional po- matin-remodeling factors such as the human homologs
tency of the AF2 receptor domain in cultured cells. The of the yeast SWI/SNF proteins (reviewed by McKenna
exact nature of the interaction of SRA with the AF1 et al., 1999). In addition, multiple coregulators associate
domain of steroid receptors is as yet unclear. SRA was with each other (Kamei et al., 1996; Spencer et al., 1997;
originally isolated in the yeast two-hybrid system, an Torchia et al., 1997), and our laboratory has shown that
assay designed to identify protein±protein interactions. distinct preformed complexes contain different sub-
In a reconstructed yeast system, SRA associated with classes of nuclear receptor coactivators in vivo (Mc-
the N-terminal domain of PR but not with a control hybrid Kenna et al., 1998). We have provided biochemical evi-
(not shown). The lack of sequence homology within the dence here that SRA elutes in a complex that also
amino terminus of steroid receptors suggests that SRA contains SRC-1 and that SRA was coimmunoprecipi-
may interact indirectly with the AF1 of the receptors as tated by SRC-1 and AR but not by p300, TR, RXR, or
part of a ribonucleoprotein complex. It is unlikely that AF1-truncated AR in the absence of SRC-1. These ob-
protein±protein interactions between the bait construct servations raise the possibility that, through a specific
and the GAL activation domain played any role in the association, SRA might function in part by modulating
isolation of SRA. Rather, we envision an interaction of the activity of a distinct class of nuclear receptor coacti-
SRA with the PR N-terminal bait, thereby recruiting it to vator complexes. Given its evident functional specificity,
the reporter gene site. The SRA-PR N terminus interac- we favor a model in which SRA confers functional selec-
tion is likely to have been supported by yeast proteins, tivity upon coactivator complexes recruited by liganded
possibly through a mediator with functional similarity receptor, possibly acting as an adaptor molecule for
to SRC-1, and such interactions would have favored type I receptors.
reporter gene activity and resulted in a positive hit. This Taken together, our results have introduced an en-
somewhat fortuitous isolation of SRA appears less puz- tirely novel concept, not only in nuclear receptor±
zling when it is considered that yeast proteins contribute regulated transactivation, but in eukaryotic transcription
functionally to transcriptional activation by steroid re- as a whole. An RNA transcript, specifically expressed
ceptors (Yoshinaga et al., 1992), even though steroid in steroid target tissues, functions as a component of
receptors are not expressed in yeast. a large multiprotein complex to selectively enhance tran-
Although we do not totally exclude the existence of scriptional activation by steroid receptors. Regulation
a translation product of SRA contained in certain cells of transcription is a modular process, probably requiring
at specific developmental stages, we have provided evi- different combinations of coregulators at different stages
dence to indicate that SRA exists and functions as an of transcription at different times. As an RNA transcript,
RNA transcript. First, we were not successful in our subjected to rapid turnover and regulation, we envisage
attempts to translate the SRA clones in vitro or in vivo. an important role for SRA in the dynamic process of
Second, an affinity column containing a mAb raised transcription in which an activated receptor recruits di-
against a sequence at the carboxy-terminal end of the verse complexes mediating temporally and spatially dis-
putative ORF1 transcript failed to detect endogenous tinct functions. Future studies will define more clearly
SRA in various cell lines tested. In addition, extensive
the functional and physiological significance of this in-
mutagenesis of SRA, introducing multiple translational
teresting eukaryotic transcriptional coregulator.
stop codons in all reading frames, did not affect the
ability of these mutants to enhance PR transactivation. Experimental Procedures
A final functional test was provided by transfection ex-
periments in the presence of cycloheximide, in which DNA Library Screening
SRA retained its ability to coactivate a reporter gene, The coding sequence of the AF1 domain of the human PRA (amino
acids 165±567 of hPRB) was subcloned into the pAS1 yeast expres-while other protein coregulators such as SRC-1 and CBP
sion plasmid in frame with the amino acid sequence of the GAL4-did not.
DBD (1±147). The yeast two-hybrid screen was performed as pre-The ability of RNA molecules to perform many func-
viously described in Onate et al. (1995). Transformants of a human
tions that were commonly attributed to proteins has B-lymphocyte cDNA expression library were tested in the Y190 yeast
been well documented. RNA molecules perform enzy- strain for interaction with progesterone-induced hPRA. RACE was
matic reactions such as trans-esterification (Jaeger, performed using the Marathon cDNA Amplification Kit (Clontech)
1997) or catalysis of peptide bond formation (Zhang and with skeletal muscle mRNA (Clontech) and the following primers: 2
strand 59-CTGGGGGATCCATCCTGGGGTGCG-39 (On1), 2 strandCech, 1997) and can regulate gene expression in trans
59-CCTGCAGCAGTGCCAGGCGTCGG-39 (On5), and 1 strand 59-by structure (Jones and Peterlin, 1994), by antisense
CGCGGCTGGAACGACCCGCCGC-39 (On3). SRA clones were iso-RNA±RNA interaction (Lee et al., 1993; Crespi et al.,
lated by homology screening of human lgt11 cDNA libraries from
1994), or by the association of two genomic-sense RNAs skeletal muscle, heart, and HeLa S3 cells (Clontech), human geno-
(Sit et al., 1998). To our knowledge, however, SRA is mic library EMBL3 SP6/T7 (Clontech), mouse heart cDNA library
different from eukaryotic transcriptional coactivators in lZAP cDNA (Strategene), and 129SVJ mouse genomic library lgtFIX
II (Stratagene) using bacteria strains and protocols as provided byits ability to function as an RNA transcript to selectively
Steroid Receptor RNA Coactivator
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the library manufacturers. Both strands of SRA clones were se- of cycloheximide. Medium was replaced 3 hr prior to transfection
with medium containing 50 mM cycloheximide and maintained untilquenced using Sequenase (Amersham) or Thermal Cycle DNA Se-
quencing (New England Biolabs). cell harvesting. Cells were transfected with the indicated DNAs using
lipofectin (Life Technologies) or SuperFect (QIAGEN) and treated
according to the manufacturer guidelines. In all transfection experi-Northern and Southern Analysis
ments, reporter plasmids were abundant (2.5 mg per 106 cells),A human tissue Northern blot (MTN, Clontech) was hybridized with
whereas nuclear receptors were transfected in limiting amountsa probe corresponding to the NaeI±HincII fragment of SRA. Tissue
(20±100 ng per 106 cells). 29-O-methoxyethyl ribose/29-deoxyribose-cell blots were prepared by isolation of total RNA using TRIzol Re-
stabilized oligonucleotides were generated by F. Bennett at ISISagent (Life Technologies) and analyzed with a 1.5 kb probe corre-
Inc., Carlsbad, CA. Fifty to two hundred nanomoles of the antisensesponding to SRA isoform III (Figure 1A). The HeLa cell blot (Figure
59-GGAACCGAGGATTATGAA-39 and corresponding sense control5) was hybridized with a random labeled fragment of the firefly
were cotransfected and treated as described for plasmid DNA. Uponluciferase cDNA. The blots were stripped and subsequently hybrid-
DNA addition, cells were cultured for 36±42 hr for CAT assays,ized with a probe specific for b-actin (MTN and tissue cell blots) or
20±24 hr for luciferase assays, and 11±14 hr in the presence ofcyclophilin (HeLa cell blot), respectively. RT-PCR products were
cycloheximide. Ligand stimulation involved incubation of cells withelectrophoresed, blotted, and hybridized with a probe correspond-
progesterone (10 nM), RU486 (50 nM), dexamethasone (50 nM),ing to isoform I of SRA. Probes were generated using random DNA
R1881 (10 nM), or estradiol E2 (10 nM) for 6±8 hr prior to cell harvest-labeling kit (Life Technologies) and 50 mCi of [a-32P]dCTP, 300 Ci/
ing. Cell lysates were assayed for CAT activity with 100 mCi ofmmol (ICN) followed by EtOH-precipitation or G-50 (Boehringer
[14C]chloramphenicol and 5 mM acetyl coenzyme A (Sigma) as sub-Mannheim) column purification.
strate and separated by thin-layer chromatography. Luciferase ac-
tivity was determined using the luciferase assay system (Promega).Plasmids
Values were corrected for protein concentration. Data are presentedThe reporter constructs (PRE)2-TATA-CAT and (ERE)2-TATA-CAT as the mean (6SD) of triplicate values obtained from a representativehave been described (Vegeto et al., 1992). The MMTV-Luc (Luc,
experiment that was independently repeated at least three times.luciferase) was generated by subcloning the Acc65I±XbaI fragment
from pGLBasic3 (Promega) into the blunt-ended EcoRI site of
Antibodies and Western AnalysisMMTV-KCR (Steve Chua, Baylor College of Medicine). The human
The mAbs against SRA, SRC-1, and hAR were prepared at the Uni-CMV-driven mammalian expression vectors pSTC for human PRB,
versity of Colorado Health Science Center in collaboration with D. P.GR, AR, and ER were generated by fusion of the cDNAs to the HSV-
Edwards. SRA-mAb was raised against the peptide sequence TAEK-TK leader sequence containing a Kozak consensus sequence (Lanz
NHTIPGFQQAS corresponding to the C terminus of the presumptiveet al., 1995); rat GR, GRDAF1, and GR-DBD have been described
ORF1 of human SRA. The mAb was purified from hybridoma culture(Rusconi and Yamamoto, 1987). PRDAF1 is an N-terminal truncation
supernatants using a mAb TRAP GII column (Pharmacia). SRC-1-of pSTC- hPRB at the AccI site and re-ligation to the blunt-ended
mAb was described previously (Spencer et al., 1997); AR-mAb rec-BamHI site of the TK leader; PRDLBD is a C-terminal truncation of
ognizes the residues 299±315 of hAR and was a gift from N. WeigelpSTC-hPRB at the DraI site. TRb, RARa, RARg, RXRg, Sp1, E2F,
(Baylor College of Medicine); the polyclonal Ab for AR-LBD (SP066;E47D, and CREB and corresponding CAT reporter constructs were
Kuiper et al., 1993) was a gift from J. Trapman and A. Brinkmann,from S. A. O. and M.-J. T. and published elsewhere (Cooney et al.,
Erasmus University, Rotterdam, The Netherlands; p300-Ab (Eckner1992; Leng et al., 1994; Onate et al., 1995); PPARg was a gift from
et al., 1994) was a gift from R. Eckner, Molecular Biology, Zurich,Steven A. Kliewer (Glaxo Research Institute) and CBP from Richard
and Sp1-Ab was obtained from Santa Cruz Biotechnology, SantaGoodman (Vollum Institute, Oregon Health Sciences University).
Cruz, CA. Immunoblotting was performed as described (Elashry-SRA-containing expression vectors were generated by subcloning
Stowers et al., 1988; Hanstein et al., 1996).the cDNAs into a modified linker of the CMV-driven pSCT-1 (Rusconi
et al., 1990). Excision of BamHI fragment of pSCT-SRA and re-
ligation generated DATG, and the fusion of the BamHI- or NaeI- Gel Filtration
Biochemical fractionation of cell lysate on a Superose 6 gel filtrationrestricted SRA to the HSV-TK leader sequence generated tk-ORF1
and tk-ORF2, respectively. The reading frame mutations ORF1, column (Pharmacia) was carried out as described (McKenna et al.,
1998) except that cell lysates contained 1±2 U/ml RNasin ribo-ORF2, and ORF3 were generated by PCR using the sense primers
59-TGGGGGATCCTACCTCAGGTGCGG-39, 59-TGGGAGATCTATCC nuclease inhibitor (Promega) and the columns were preequilibrated
with RNasin. For antibody shift experiments, clarified lysates wereTAGGGTGCGG-39, and 59-TGGGGGATCCTACCTAGGGTGCGG-39,
followed by restriction subcloning into pSCT-SRA. YIle used the preincubated at 48C with 2 mg of SRC-1 mAb and a 4-fold excess
of rabbit anti-mouse IgG (Zymed). Half of each column fraction (400primer 59-ATAGCAATTGGGCCTCCACCTCCTTCAAG-39 to destroy
an ATG and to introduce an MfeI site in mutant ORF2. Frameshift ml) was processed for RNA isolation and RT-PCR analysis, while
the other portion was precipitated with BSA/trichloracetic acid, sep-mutations were generated by restriction of SRA or mutant ORF2
with selected enzymes, filled in with Klenow DNA polymerase, and arated on 7.5% polyacrylamide gels, and transferred overnight to
nitrocellulose membrane (BioRad) at 08C±48C for Western analysis.re-ligated at the following sites: BbsI (generated mutant B), SgrAI
(S), MfeI and SgrAI (MS, YMS), and MfeI, BbsI, and SgrAI (YMBS).
39 deletions at BbsI of ORF1, ORF2, and ORF3 generated DORF1, SRA-Specific RT-PCR
DORF2, and DORF3. All the vectors for in vitro transcription (Figure Cell extracts (20±30 ml) or column fractions (200 ml) were supple-
6C) were generated by subcloning the cDNAs for SRA, SRC-1, AR, mented with 5 mM MgSO4 and incubated for 25 min at 378C with
and Sp1 into MS2, which is a modified version of pSP64 poly(A) 20±40 U RNase-free DNaseI (Boehringer Mannheim) and 1±2 U/ml
(Promega) containing an additional polylinker 39 of the poly(A) se- RNasin ribonuclease inhibitor (Promega). Total RNA was extracted
quence for linearization of the plasmid. ARDAF1 was generated using 1 ml TRIzol Reagent and processed according to the manufac-
by subcloning of the HindIII±XbaI fragment encoding amino acids turer's protocol (Life Technologies). EtOH-washed RNA was resus-
605±910 of pAR65 (Jenster et al., 1993) into MS2. pMS2-p300 was pended in 12 ml 2 pmol SRA-specific primers (On3: 59-CGC
from J. W. (unpublished), and pMS2-TR and pMS2-RXR have been GGCTGGAACGACCCGCCGC-39 and On8: 59-CAGACTCACCGGAC
described (Wong et al., 1995). ACCATCTCCTA-39; see Figure 2). First-strand cDNA synthesis was
generated using Moloney reverse transcriptase and reagents sup-
plied with the SuperScript II Kit (Life Technologies). Twenty percentCell Culture and Transient Transfection Assays
Cell lines were routinely maintained at 378C/5% CO2 in Dulbecco's (4 ml) of the reaction was used in a 50 ml PCR amplification using
5 U of Taq-DNA polymerase (Promega), 2 mM MgCl2, 150 mM dNTPs,modified Eagles' medium (HeLa, COS) or RPMI medium 1640 (T-47D)
supplemented with 5%±10% charcoal-stripped fetal calf serum. 105 1 mM of primers (On3/On8). PCR was performed as follows: 3 min
at 958C, 25±40 cycles of 30 s at 958C, 45 s at 588C, 40 s at 718C,cells were plated out per well in 12-well dishes for luciferase assays,
5 3 105 cells per well in 6-well dishes for CAT assays, and 106 cells and 5 min at 728C. Alternatively, RNA from immunoprecipitations
was processed by using the SuperScript One-Step RT-PCR Systemper 10 cm dish for assays that involved cell culture in the presence
Cell
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(Life Technologies) and incubated at 508C for 30 min prior to cDNA in breast cancer with anti-human receptor monoclonal antibodies.
Cancer Res. 48, 6462±6474.amplification. PCR products were visualized on 1.2% agarose/TAE
gels and blotted to Zeta-Probe GT membrane (BioRad) by alkaline Halachmi, S., Marden, E., Martin, G., MacKay, H., Abbondanza, C.,
transfer for Southern analysis. and Brown, M. (1994). Estrogen receptor-associated proteins: possi-
ble mediators of hormone-induced transcription. Science 264, 1455±
1458.Immunoprecipitation in Xenopus laevis Oocytes
pP(A)LiSK-cDNA constructs were transcribed in vitro with SP6 RNA Hanstein, B., Eckner, R., DiRenzo, J., Halachmi, S., Liu, H., Searcy,
polymerase and the mMessage mMachine kit (Ambion) to generate B., Kurokawa, R., and Brown, M. (1996). p300 is a component of an
200±400 mg/ml specific mRNA. Xenopus laevis oocytes were injected estrogen receptor coactivator complex. Proc. Natl. Acad. Sci. USA
with 27.6 nl specific mRNA and L-35S-methionine and cultured for 93, 11540±11545.
12±16 hr at 188C in MBSH [10 mM HEPES {pH 7.6}, 88 mM NaCl, 1 Horwitz, K.B., Jackson, T.A., Bain, D.L., Richer, J.K., Takimoto, G.S.,
mM KCl, 2.4 mM NaHCO3, 0.82 mM MgSO4, 0.41 mM CaCl2, 0.33 and Tung, L. (1996). Nuclear receptor coactivators and corepres-
mM Ca(NO3)2]. Oocytes were lysed in extract buffer (20 mM HEPES sors. Mol. Endocrinol. 10, 1167±1177.
[pH 7.6], 70 mM KCl, 2 mM DTT, 0.1% NP-40, 8% Glycerol, 1 mM
Jaeger, L. (1997). The new world of ribozymes. Curr. Opin. Struct.PMSF, and 1 U/ml RNasin) in a ratio of 10 ml extract buffer per
Biol. 7, 324±335.oocyte. Clear lysates were incubated with 4 mg of SRC-1-mAb, 2
Jenster, G., Trapman, J., and Brinkmann, A.O. (1993). Nuclear importmg of AR-mAb, 8 ml of SP066 (AR-LBD Ab), 4 mg of rabbit polyclonal
of the human androgen receptor. Biochem. J. 293, 761±768.Sp1-Ab, or 4 mg of rabbit polyclonal TR-Ab together with a 4-fold
excess of rabbit anti-mouse IgG (Zymed) for 35 min at 48C followed Jonat, C., Rahmsdorf, H.J., Park, K.K., Cato, A.C., Gebel, S., Ponta,
by 30 min incubation at 48C with protein A±Sepharose (Pharmacia) H., and Herrlich, P. (1990). Antitumor promotion and antiinflamma-
that was washed and equilibrated in extract buffer. Subsequently, tion: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid
beads were washed five times with 5 vol of extract buffer, and bound hormone. Cell 62, 1189±1204.
material was analyzed by RT-PCR and by SDS-PAGE. Jones, K.A., and Peterlin, B.M. (1994). Control of RNA initiation and
elongation at the HIV-1 promoter. Annu. Rev. Biochem. 63, 717±743.
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